Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and immune diseases, today announced the presentation ofin vivo data for its first-in-class MALT1 degrader, TE205, as adisease-modifying therapy for ulcerative colitisat the4th International Conference on Microbiology and Immunologyin Las Vegas, Nevada.
https://mma.prnewswire.com/media/2189834/Eilean_Therapeutics_Logo.jpg
Preclinical FindingsIn preclinical studies,TE205demonstrated a robust and multifacetedimmunomodulatory effectin the DSS-induced colitis model, achieving bothstructural and functional restoration of intestinal integrity.
By selectively degradingMALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), TE205 effectively:
— Suppressed NF-kB signaling and pro-inflammatory cytokine production,
— Rebalanced key T-cell and macrophage populations within the lamina propria, and
— Restored epithelial barrier function and mucosal architecture.
Collectively, these results establish TE205 as apotent, first-in-class MALT1 degraderwith strongin vivo efficacyandclear disease-modifying potentialfor inflammatory bowel disease (IBD).
AboutEilean TherapeuticsEilean Therapeutics LLCis a biopharmaceutical company focused on the discovery and development ofbest-in-class and first-in-class small-molecule therapiesaddressing genetic and signaling vulnerabilities in hematologic malignancies, solid tumors, and chronic inflammatory diseases.
Leveraging itsproprietary AI/ML-driven hybrid drug design platform, Eilean integrates partner datasets, advanced chem-bio modeling, and deep translational expertise to identify high-value molecular targets, accelerate discovery timelines, and advance differentiated, mechanism-based therapies.
Eilean's development-stage pipeline includes:
— First-in-class MALT1 degraders and best-in-class BTK inhibitors for ulcerative colitis and B-cell malignancies, and
— Selective, wild-type-sparing JAK2 V617F inhibitors for the treatment of myelofibrosis and polycythemia vera.
For more information, please visitwww.eileanther.com.
Media Contact:Amy Burd, PhDChief Scientific OfficerEilean Therapeutics LLCaburd@eileanther.com
https://edge.prnewswire.com/c/img/favicon.png?sn=LA15684&sd=2025-11-04
View original content to download multimedia:https://www.prnewswire.com/news-releases/eilean-therapeutics-presents-first-in-class-malt1-degrader-te205-demonstrating-in-vivo-efficacy-in-ulcerative-colitis-at-the-4th-international-conference-on-microbiology-and-immunology-302604708.html
SOURCE Eilean Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=LA15684&Transmission_Id=202511041625PR_NEWS_USPR_____LA15684&DateId=20251104